403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Oncolytics Biotech Inc
(MENAFN- Baystreet) 11:21 AM EST - Oncolytics Biotech Inc: Announced clinical and translational findings supporting the development of pelareorep in second-line metastatic colorectal cancer, specifically in patients with KRAS-mutant, microsatellite-stable disease. This represents one of the most difficult-to-treat and least responsive subgroups within colorectal cancer. Oncolytics Biotech Inc
shares N are trading up $0.06 at $0.98.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment